Search Within

Genitourinary Oncology Service

  1. "Radiochemistry and Imaging Sciences Service"
Formats
  1. Journal Article (43)
  2. Meeting Abstract (23)
  3. Book Section (1)
  4. Review (1)
Groups
  1. Department of Medicine (68)
  2. Radiochemistry and Imaging Sciences Service (68)
  3. Radiology, Department of (68)
  4. Solid Tumor Oncology Division (68)
  5. GSK Faculty (62)
  6. Medical Physics (40)

More Groups

People
  1. Jason Lewis (35)
  2. Michael Morris (35)
  3. Steven Larson (26)
  4. Serge Lyashchenko (23)
  5. Howard Scher (22)
  6. Neeta Pandit-Taskar (21)

More People

Years
  1. 2025 (2)
  2. 2024 (1)
  3. 2023 (3)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (6)

More Years

Publications
  1. Journal of Nuclear Medicine (15)
  2. Journal of Clinical Oncology (14)
  3. Cancer Research (5)
  4. Clinical Cancer Research (4)
  5. NMR in Biomedicine (3)
  6. Proceedings of the National Academy of Sciences of the United States of America (3)

More Publications

Publishers
  1. Society of Nuclear Medicine (15)
  2. American Society of Clinical Oncology (14)
  3. American Association for Cancer Research (12)
  4. John Wiley & Sons (5)
  5. National Academy of Sciences (3)
  6. Wiley Blackwell (3)

More Publishers

Results (68)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways
    Journal Article

    Hirani, R.; Nandakumar, S.; Zaman, N.; Prabhakaraalva, P.; King, S. A.; Kalidindi, T. M.; Ghale, R.; Rajanala, S. H.; Fidele, D. C.; De Stanchina, E.; more...
    Cell Reports (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: A phase 1/2, first-in-human trial
    Journal Article

    Tendler, S.; Dunphy, M. P.; Agee, M.; O'Donoghue, J.; Aly, R. G.; Choudhury, N. J.; Kesner, A.; Kirov, A.; Mauguen, A.; Baine, M. K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Case study #8: Alpha-therapy with radium-223 dichloride for metastatic castration-resistant prostate cancer
    Book Section

    Pasquini, L.; Morris, M. J.; Bodei, L.
    In Bodei, L.; Lewis, J. S.; Zeglis, B. M. (Eds.) Radiopharmaceutical Therapy (2023)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3
    Journal Article

    Korsen, J. A.; Kalidindi, T. M.; Khitrov, S.; Samuels, Z. V.; Chakraborty, G.; Gutierrez, J. A.; Poirier, J. T.; Rudin, C. M.; Chen, Y.; Morris, M. J.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer
    Journal Article

    Chakraborty, G.; Nandakumar, S.; Hirani, R.; Nguyen, B.; Stopsack, K. H.; Kreitzer, C.; Rajanala, S. H.; Ghale, R.; Mazzu, Y. Z.; Pillarsetty, N. V. K.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer
    Journal Article

    Korsen, J. A.; Gutierrez, J. A.; Tully, K. M.; Carter, L. M.; Samuels, Z. V.; Khitrov, S.; Poirier, J. T.; Rudin, C. M.; Chen, Y.; Morris, M. J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2022)

    Fulltext@MSK | Save